News

Stem cell fluid shows promise as PAH treatment, study finds

Stem cell-derived conditioned medium, or the liquid that remains after cells are cultured, reduces the signs of pulmonary arterial hypertension (PAH) in rat and cell models, a study showed. “These findings support [stem cell]‐derived conditioned medium as a promising therapeutic strategy for PAH, warranting further investigation in translational studies…

Higher pulmonary arterial pressure is problem for pregnant women

For pregnant women with pulmonary hypertension (PH), higher pulmonary arterial pressure — blood pressure levels in the blood vessels that supply the lungs — is associated with longer hospital stays and a greater chance of being admitted to the intensive care unit (ICU). That’s according to a new study…

Underweight infants with PH at high risk for eye disease: Study

Underweight infants with pulmonary hypertension (PH) are at increased risk of developing retinopathy of prematurity (ROP), a leading cause of childhood blindness, according to a study. However, the prevalence of severe ROP was 18% lower in PH infants who received treatment with inhaled nitric oxide (iNO). “While iNO is…

Tenax sees European patent for levosimendan to treat PH-HFpEF

The European Patent Office has given Tenax Therapeutics notice that it plans to grant a patent covering the use of levosimendan and its active metabolites to treat pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), the company said. TNX-103, an oral formulation currently in Phase…

6-part special podcast series aims to raise awareness of Meth-PAH

Phaware, a global advocacy organization, is launching a special podcast series to raise awareness of pulmonary arterial hypertension (PAH) caused by the use of methamphetamine, a stimulant drug known for its psychoactive effects. Methamphetamine-induced PAH is now known simply as Meth-PAH. The six-episode series, part of the “…

PEA surgery may be more effective than BPA for CTEPH: Study

Pulmonary endarterectomy (PEA), a surgery to remove blood clots in individuals with chronic thromboembolic pulmonary hypertension (CTEPH), may be more effective in improving pulmonary circulation and heart function than balloon pulmonary angioplasty (BPA), according to a recent study. After treatment, a higher proportion of patients in the BPA group…

Stanford awarded NIH grant for PAH treatment clinical trial

Stanford University has been awarded a grant from the U.S. National Institutes of Health (NIH) to begin a Phase 2 clinical trial of pulmonary arterial hypertension (PAH) treatment tiprelestat, the treatment’s developer announced. Tiakis Biotech said tiprelestat was found to be safe in earlier clinical trials involving more…